In a preclinical model for prostate cancer gene therapy, we have tested lentiviral vectors as a practical possibility for the transfer and long-term expression of the EGFP gene both in vitro and in vivo. The human prostate cancer cell lines DU145 and PC3 were transduced using experimental conditions which permitted analysis of the expression from a single proviral vector per cell. The transduced cells stably expressed the EGFP transgene for 4 months. After injection of the transduced cell populations into Nod-SCID mice a decrease in EGFP was only observed in a minority of cases, while the majority of tumors maintained transgene expression at in vitro levels. In vivo injection of viral vector preparations directly into preestablished subcutaneous or orthotopic tumor masses, obtained by implantation of untransduced PC3 and DU145 cells led to a high transduction efficiency. While the efficiency of direct intratumoral transduction was proportional to the dose of virus injected, the results indicated some technical limitations inherent in these approaches to prostate cancer gene therapy.
Introduction
The treatment of prostate carcinoma, the most frequent cancer and the second ranked cause of mortality in men in the Western society, still requires the development of new therapeutic approaches. Gene therapy, applied separately or in conjunction with current treatment modalities has shown promise as one such alternative. [1] [2] [3] [4] For this purpose, gene transfer strategies designed to suppress tumor growth using either suicide genes, proapoptotic genes or gene-based immunotherapy have all been proposed. [5] [6] [7] [8] Human immunodeficiency virus (HIV) type 1-derived vectors have emerged as potential candidate vectors for cancer gene therapy, since they combine the transduction of nondividing cells and integration of the transgene into the genome of the target cell. This should allow, with appropriate targeting, long-term or reiterated treatments of localized disease or the treatment of metastases. 9, 10 In the present study, we have tested the ability of HIVderived lentiviral vectors to transfer a therapeutic gene into human prostate cancer cells, and the longevity of transduced gene expression, in vitro and in vivo, using Nod/SCID mice. To monitor expression, the enhanced green fluorescent protein (EGFP) gene originally from the jellyfish Aequoria victoria was used as a model. The GFP gene encodes a 238-amino-acid polypeptide, which contains a natural chromophore. At specific excitation wavelengths, cells expressing GFP proteins were detected by fluorescence microscopy or by flow cytometry, permitting both quantification and cellular localization studies. 11 We conclude that HIV-1-derived lentiviral vectors containing the EGFP gene as a reporter gene can transduce human prostate cancer cell lines in vitro. The expression of the transgene was assayed both in vitro, and in cells derived from implanted tumors obtained in a relevant preclinical animal model in Nod/SCID mice we have recently described.
Methods
Cell lines and culture conditions PC-3 (ATCC, CRL1435) was cultured in F12.K medium complemented with 1% l-glutamine, 1% antibiotics (penicillin, 10 000 UI/ml; streptomycin 10 000 UI/ml), 2% sodium bicarbonate, and 10% fetal calf serum. DU145 (ATCC, HTB81) was cultured in minimum essential medium complemented with 1% sodium pyruvate, 1% nonessential amino acids, 1% antibiotics (penicillin, 10 000 UI/ml; streptomycin 10 000 UI/ml), 2% sodium bicarbonate, and 10% fetal calf serum. The cells were maintained at 371C in a 5% CO 2 containing atmosphere.
Tumor implantation in Nod-SCID mice and follow-up Nod-SCID mice were kindly provided by John E Dick (Children's Hospital, Toronto, Canada). Subcutaneous implantation of cell suspension was performed without anesthesia in the thoracic postero-lateral wound. Tumor cells (2 Â 10 6 ) were suspended in 100 ml of PBS and injected into the animal using a 30-gauge needle and a 1-ml disposable syringe. For orthotopical implantation in the prostate gland, 1 million cells suspended in 50 ml of PBS were injected into a dorsal prostatic lobe using a 30-gauge needle and a 1-ml disposable syringe under surgical sterile conditions. Tumor progression was monitored by palpation two times a week by the same investigator. The size of the subcutaneous tumor was measured using a caliper. Animals were killed according to the size of the tumor or to the clinical status during the observation period. An autopsy was performed systematically after orthotopic implantation to assess the distribution of metastases. Harvested prostate tumors and metastases were divided into two pieces, of which one was seeded into culture and the other fixed in 10% formalin for histological analysis.
Gene transfer procedure and transgene expression assay
In vitro transduction of PC-3 and DU145 was performed using LentiHRcmvEGFP and LentiHRpgkEGFP. LentiRRLpgkEGFPsin18, a third generation self-inactivating lentiviral vector was used for in vivo tumor transduction. Lentiviral vector constructs and packaging plasmids were a generous gift from D Trono (University of Geneva, Geneva). 13 Technical procedures to generate lentiviral vector containing supernatants and estimate the viral titer have already been described. 14 Transduction in vitro was performed as follows. On day 1, cells were seeded at 1 Â 10 5 cells/well in 12-well dishes in culture medium containing 4 mg/ml polybrene. After 5 h, culture medium was supplemented with virus containing supernatants according to the selected multiplicity of infection (MOI). After 18 h, the culture medium used for transduction was replaced with fresh medium.
At day 5, cells were trypsinized and EGFP expression was assessed by flow cytometry (FACScalibur, Becton Dickinson).
In vivo gene transfer was performed by intratumoral injection of 50-100 ml of LentiRRLpgkEGFPsin18 containing supernatants according to the size of the tumor between the fifth and the seventh week of tumoral growth after implantation. Subcutaneous tumors were directly injected through the skin and orthotopic tumors were injected following a surgical procedure. Animals were killed 3 days or 3 weeks after injection. Tumors and metastases were cut out with a scalpel and incubated for 1 h at 371C in PC-3 or DU145 culture medium supplemented with 2.5 mg/ml trypsin and 0.5 mg/ml collagenase II. The cell suspension was sifted through Sieve Nylon (70 mm in diameter). The filtrate obtained was centrifuged at 1600 rpm for 10 min, and cells in the pellet were cultured in their respective medium. All tumors and metastasis withdrawn from animals were placed into culture within 24 h of excision.
Results

Transduction of cell lines and long-term expression of the transgene in vitro
LentiHRcmvEGFP and LentiHRpgkEGFP, two first-generation lentiviral vectors, were tested for their ability to transduce PC-3 and DU145, two human prostate cancer cell lines in vitro, and to express the EGFP marker gene (Figure 1a,b) . In LentiHRcmvEGFP and LentiHRpgkEGFP, expression of the EGFP coding sequence is under the control of ubiquitous promoters derived from the cytomegalovirus or from the human phosphoglycerate kinase gene, respectively. Both vectors were able to transduce PC-3 and DU145, but as assessed by the percentage of EGFP positive cells, DU145 was much more efficiently transduced by LentiHRpgkEGFP than to PC-3 ( Figure 2 ). Conversely, experiments carried out with LentiHRcmvEGFP showed similar transduction efficiency regardless of the cell line. 65 and 90% of EGFP positive DU145 cells were obtained with transduction To analyze the expression of the transgene at a maximum level of one proviral integration per cell, transduction experiments were then performed at low MOI to obtain a cell population containing a very low percentage of EGFP-positive cells. 15 Estimation by FACS analysis of the mean fluorescent intensity of EGFP in DU145 and PC-3 cell populations exhibiting less than 10% of EGFP cells (Figure 3 ) showed no marked difference between the EGFP expression driven by either the promoter. A slightly higher expression of the transgene was observed in the PC3 cells compared to DU145. No morphological changes were detected between native and virally transduced cells in the two cell lines under all conditions tested (data not shown).
Lentiviral vector transduction allows long-term expression of the EGFP marker gene in vitro
The expression of the EGFP gene in the cell populations, as assessed by the percentage of EGFP-positive cells and the mean fluorescence intensity, peaked at 72 h after the transduction procedure and then plateaued (data not shown). Long-term expression of the transgene was analyzed in cells transduced with LentiHRpgkEGFP 
In vivo lentivirus transduction of prostate cancer cells in subcutaneous or orthotopic tumors
As a model procedure for prostate cancer gene therapy, subcutaneous and orthotopic tumors obtained following injection of native PC-3 and DU145 cells were directly transduced in vivo with LentiRRLpgkEGFPsin18. LentiRRLpgkEGFPsin18 is a secured vector, which exhibits a self-inactivating structure making it suitable for clinical trials (Figure 1c ).
Subcutaneous tumor transduction
Seven subcutaneous tumors; three tumors obtained with PC-3 cells and four tumors with DU145 cells, were transduced during the sixth week of tumor growth. The volume of viral vector-containing supernatant injected in both models of tumor was 100 ml containing 1.5 Â 10 8 transducing units (tu) per ml for DU145 tumors, and 50 ml with 1 Â 10 8 tu/ml for PC-3 tumors. The tumors were harvested and placed into culture 72 h after the injection of the lentiviral vector-containing supernatant. Three subcutaneous DU145 tumors obtained with DU145 and two tumors obtained with PC-3 were assayed for EGFP expression for 3 weeks. Percentages of fewer than 1% of the cultured cells expressed (high) levels of EGFP at levels comparable to those obtained after in vitro transduction.
Orthotopic tumor transduction
A total of 11 orthotopic tumors, five tumors obtained with PC-3 cells and six tumors obtained with DU145 cells, were assayed for transduction during the sixth week of tumor growth. Volumes of 100 and 50 ml of viral vector containing supernatant, respectively, were injected into tumors obtained with DU145 and PC-3 cells, respectively, with 1.5 Â 10 8 tu/ml for DU145 tumors, and 1 Â 10 8 tu/ml for PC-3 tumors. Six tumors (three During autopsy, 14 metastases located in the retroperitoneal lymph node, the liver, the pancreas, the kidney, the adrenal, the lung, and the diaphragm for PC-3 injected animals and the retroperitoneal lymph node, the hepatic vessels, the kidney, the wound lumbar, and the diaphragm for DU145 injected animals, were withdrawn and metastatic cells were seeded into culture. Since the in vivo context has been shown to dramatically affect the expression of a therapeutic transgene, we also studied the kinetics of EGFP expression of cells reimplanted in vivo for several weeks. FACS analysis of EGFP expression in genetically manipulated cells harvested from tumors or metastases showed various expression profiles, suggesting that the in vivo context does indeed strongly affect the expression kinetics of these transgene. Molecular mechanisms, including DNA hypermethylation, 14, 16 mutations localized in the cDNA of the transgene or in the promoter, 17, 18 the impact of the cellular protein context, 19 combined with the selection of cell populations in vivo due to a potential toxic effect of the transgene in some conditions 20 can dramatically impact the expression kinetics of the transgene. Whether these mechanisms alone or in combination can explain the modification of the EGFP expression kinetics in this model remains to be explored. 16 Intratumoral injection of lentiviral vectors is another major issue addressed in this study. In our model, the injection of viral vector suspension into orthotopic tumors was performed under surgical conditions to mimic the strategy to be used for the intratumoral injection of therapeutic products in human. Even if the absolute transduction efficiency remains low, relative to the total number of viral particles injected, some orthotopic tumors exhibited very high transduction efficiency, as assessed by the percentage of EGFP expressing cells (5 and 11% for two PC-3 tumors). In contrast the subcutaneous tumors only showed moderate transduction efficiency with maximum 1% EGFP positive cells strongly expressing the transgene. A lack of EGFP fluorescence in metastases derived from the original cancers in the orthotopic injection is most likely due to the early extraprostatic spread of the original PC3 and DV145 cellular inoculations before lentiviral injection.
Altogether our results highlight some of the technical aspects, which can be improved to make this procedure an eligible therapeutic strategy for preclinical and clinical approaches. For example, the use of highly concentrated viral stocks would favor the diffusion of the viral vector through the tumor mass and would improve the transduction efficiency in vivo. 21 However, it should be noted that such a strategy raises safety concerns, since it may increase the transduction of normal cells. To overcome unwanted expression of the exogenous transgene in normal cells, the viral particles must be targeted to the tumor cells, or the transcription of the therapeutic transgene must be restricted by the use of more specific promoters. 5 Since engineering of viral particles to transduce selected cells dramatically alters the transduction efficiency of retroviral-based vectors, expression strategies using tissue-specific promoters such as the prostate specific antigen promoter should be favored as a preliminary step. 9 Finally, although a single-strategy approach is tested in the present article, it should be emphasized that the synergy of strategies such as radiotherapy, chemotherapy or cell therapy combined with gene therapy could be considered as a key parameter to produce successful therapeutic approaches. For example, the combination of the surgical resection of tumor masses with the stimulation of an immune response through the genetic manipulation of, for example dendritic cells, has shown potential as a treatment of prostate cancer metastases. 22, 23 Such a treatment regime will depend upon improvements in specific technical aspects such as transduction efficiency, but also tumor targeting as an overall strategy.
